IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of   :

Kelsall et al.   :

Serial No.: 09/196,867   :   Group Art Unit: 1642

Filed: November 20, 1999   :

For: METHODS OF USING CR3 AND CR4   :
       LIGANDS FOR INHIBITING   :
       INTERLEUKIN-12 TO TREAT   :
       AUTOIMMUNE DISEASE   :

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811

August 18, 2000

Sir:

. Submitted herewith on form PTO 1449 is a listing of a document known to applicants and/or their attorneys in compliance with the requirements of 37 C.F.R. § 1.56. Applicants certfy that the cited document was not known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of this statement. A copy of this document is enclosed.

Consideration of the cited document and making the same of record in the prosecution of the above-noted application are respectfully requested.

It is believed that this paper is being timely filed and that no fee is required for the filing thereof. However, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.

Mary L. Miller

Mary L. Miller
Registration No. 39,303

NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811
404/688-0770

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on August 18, 2000.

Mary L. Miller   _August 18, 2000_
Mary L. Miller   Date